11
Feb
2010
Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Oncology
Morvus Technology (United Kingdom) a preclinical-stage pharmaceutical company focused on prodrug and anti-angiogenic oncology approaches, closed a $3.3M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb